SCHEMBL5409626

SCHEMBL5409626

CCOC(=O)c1cc(Cl)cc(O)c1N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.54
GAA P10253 8/20 0.54
KDM4E B2RXH2 7/20 0.54
HPGD P15428 5/20 0.54
GLA P06280 4/20 0.54
NPSR1 Q6W5P4 1/20 0.51
CA1 P00915 4/20 0.49
CA2 P00918 4/20 0.49
CA12 O43570 3/20 0.49
CA9 Q16790 3/20 0.49
CA7 P43166 2/20 0.49
CA14 Q9ULX7 2/20 0.49
HSD17B10 Q99714 2/20 0.46
MAPK1 P28482 2/20 0.45
MAPT P10636 1/20 0.45
NR1H2 P55055 1/20 0.45
NR1H3 Q13133 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TSHR P16473 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6948296 0.85 ALDH1A1 (0.55) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL16529438 0.85 ALDH1A1 (0.55) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL9727774 0.85 ALDH1A1 (0.71) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL29264039 0.84 ALDH1A1 (0.54) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL25234783 0.83 CA1 (0.51) ALDH1A1KDM4ECA1CA2CA12
SCHEMBL3585477 0.83 ALDH1A1 (0.52) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL28825145 0.83 ALDH1A1 (0.53) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL1003428 0.81 ABL1 (0.53) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL30361197 0.81 CA1 (0.52) ALDH1A1GAAKDM4EHPGDGLA
SCHEMBL26466636 0.81 CA1 (0.52) ALDH1A1GAAKDM4EHPGDGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-04-20 US disclosed
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-04-20 US disclosed
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-04-20 US disclosed
EP-3109239-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-12-28 EP disclosed
CN-105980363-A Aminopyrazolone Derivatives 第三共株式会社 2016-09-28 CN disclosed
WO-2015125786-A1 AMINOPYRAZOLONE DERIVATIVE 第一三共株式会社 2015-08-27 WO disclosed
US-RE43481-E1 Diazepan derivatives or salts thereof ASTELLAS PHARMA INC. (JP) 2012-06-19 US disclosed
US-7307074-B2 Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration ASTELLAS PHARMA INC. (JP) 2007-12-11 US disclosed
US-7307074-B2 Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration ASTELLAS PHARMA INC. (JP) 2007-12-11 US disclosed
US-7307074-B2 Activated blood coagulation factor X inhibitor and also to such a pharmaceutical agent and particularly has an excellent activity by oral administration ASTELLAS PHARMA INC. (JP) 2007-12-11 US disclosed
EP-1415990-B1 Diazepan derivatives useful as factor X inhibitor ASTELLAS PHARMA INC (JP) 2006-09-20 EP disclosed
EP-1415990-A1 Diazepan derivatives useful as factor X inhibitor YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-05-06 EP disclosed
US-20040068109-A1 Diazepan derivatives or salts thereof YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-04-08 US disclosed
US-6642224-B1 Diazepan derivatives or salts thereof YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2003-11-04 US disclosed
US-20030195193-A1 Diazepane derivatives or salts thereof ASTELLAS PHARMA INC. (JP) 2003-10-16 US disclosed
EP-1273575-A1 DIAZEPANE DERIVATIVES OR SALTS THEREOF YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2003-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195193-A1 Diazepane derivatives or salts thereof F10, F11, SERPINC1 ALDH1A1 2532/4885GAA 2852/4885KDM4E 482/4885
US-20040068109-A1 Diazepan derivatives or salts thereof F10, SERPINC1, F11 ALDH1A1 2524/4885GAA 2581/4885KDM4E 338/4885
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE ATAD5, ATP1A1, TIPRL ALDH1A1 2821/4885GAA 2530/4885KDM4E 1929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.